Skip to main content
Cell Death & Disease logoLink to Cell Death & Disease
. 2016 Jun 9;7(6):e2259. doi: 10.1038/cddis.2016.147

ATP2C1 gene mutations in Hailey–Hailey disease and possible roles of SPCA1 isoforms in membrane trafficking

M Micaroni 1,*, G Giacchetti 2,3, R Plebani 2,4, G G Xiao 1, L Federici 2,4
PMCID: PMC5143377  PMID: 27277681

Abstract

ATP2C1 gene codes for the secretory pathway Ca2+/Mn2+-ATPase pump type 1 (SPCA1) localizing at the golgi apparatus. Mutations on the human ATP2C1 gene, causing decreased levels of the SPCA1 expression, have been identified as the cause of the Hailey–Hailey disease, a rare skin disorder. In the last few years, several mutations have been described, and here we summarize how they are distributed along the gene and how missense mutations affect protein expression. SPCA1 is expressed in four different isoforms through alternative splicing of the ATP2C1 gene and none of these isoforms is differentially affected by any of these mutations. However, a better understanding of the tissue specific expression of the isoforms, their localization along the secretory pathway, their specific binding partners and the role of the C-terminal tail making isoforms different from each other, will be future goals of the research in this field.

Facts

  • Mutations occurring on the ATP2C1 gene clearly have no hotspots, although some mutations are redundant and the majority of missense mutations are spotted on specific exons.

  • The C-terminal tails of two out of four SPCA1 isoforms display a sequence motif recognized by PDZ domains, potentially used to interact with different pools of protein and involved in different signaling pathways.

  • SPCA1 has important roles in regulating membrane trafficking, not only as a Ca2+ pump able to trigger the Ca2+ influx into the lumen of the golgi apparatus (and of consequence the cytosolic peri-golgi Ca2+ concentration/signaling), but it also has a direct role in organizing cargo maturation/delivery from the golgi apparatus, which is imbalanced in cancer and other diseases.

Open Questions

  • Why mutations on the ATP2C1 gene cause a different etiology between human and mouse? Does the overlap of ATP2C1 gene with ASTE1 gene have a role in regulating the SPCA1 expression in a different manner between species?

  • Identification of proteins interacting with the C-terminal tails of the SPCA1 isoforms, and their possible role in mediating the function and the sub-organellar redistribution of the different SPCA1 isoforms in different cell types.

  • Although SPCA1 is ubiquitously expressed in all the tissues, why mutations occurring on the ATP2C1 gene are mostly affecting the skin?

The study of intracellular membrane trafficking is important for the understanding of cellular structure and organelle function, and the coordinated cellular activities within complex organisms. The intracellular transport can be divided into different phases, which include the synthesis of lipids and proteins in the endoplasmic reticulum (ER), their folding and quality control, transport from ER-to-golgi apparatus and across the golgi apparatus, and delivery of cargoes to their final destinations. The golgi apparatus also participates in the post-translational modifications (mostly glycosylation) of many proteins and lipids during their transport, and it is the central station of the intracellular secretory pathway.1, 2

The physiology of the secretory pathway and the golgi apparatus is finely regulated and maintained by pumps and channels that maintain the luminal pH/ion levels, making each sub-compartment of the golgi unique (i.e., the cis-side of the golgi apparatus is different from the trans-side).3 The secretory pathway Ca2+-ATPase pump type 1 (SPCA1) regulates the golgi luminal Ca2+ homeostasis, it is distributed along the secretory pathway membranes4 and ubiquitously expressed in all tissues.5

The human ATP2C1 gene encoding for SPCA1 is located on chromosome 3q21 and consists of 28 exons.6, 7 Alternative processing at the 3′-end of the human ATP2C1 pre-mRNA produces four distinct ATP2C1 splice variants (corresponding to SPCA1a-d proteins; Figure 1a), namely (i) SPCA1a from the splicing of exon 26 to exon 27 with the translation stop codon located in exon 27 producing a protein of 919 amino acids; (ii) SPCA1b which contains 939 amino acids and results from splicing of exons 27 to 28 following activation of the internal 5′-splice donor site D1; (iii) splicing of exons 26–28 gives rise to SPCA1c, which has 888 amino acids; (iv) splicing at internal site D2 in exon 27 to exon 28 gives rise to SPCA1d, which is the largest variant with 949 amino acids (Figure 1a′).

Figure 1.

Figure 1

Representation of the ATP2C1 gene alternatively spliced and the molecular structure of encoded SPCA1. (a) The ATP2C1 gene consists of twenty-eight exons (represented by boxes), which are alternatively spliced as indicate by the internal 5′ donor splice sites, D1 and D2 generating four different mRNA. Diagonal lines illustrate the slicing patterns generating splice variants ATP2C1a-d. (a′) The ATP2C1a-d splice variants are schematically represented. (a) and (a′) are modified from Micaroni and Malquori.50 (b) Actuator domain (A), phosphorylation domain (P), nucleotide-binding domain (N) and 5 stalk helices (S) in the cytoplasm, and 10 transmembrane helices (M). This figure was adapted from Matsuda et al.8 (c) In gray is the exon 26, in yellow the exon 27, in green the exon 28. According to the present literature, the isoform SPCA1c seems not be coded in a protein. This isoform is missing the exon 27 coding for the transmembrane 10 (M10). Furthermore, this isoform is missing the possibility to have a cytosolic C-terminal tail where potential binding sites for other proteins is present, reinforcing the idea that this isoform is not functional. Hs-SPCA1a (NP_055197); Hs-SPCA1b (NP_001001487.1); Hs-SPCA1c (NP_001001485.2); Hs-SPCA1d (NP_001001486.1); Pt-SPCA1 (XP_001145788.1); Cl-SPCA1 (XP_534262.2); Mm-SPCA1 (NP_778190.3); Rn-SPCA1 (NP_571982.2); Gg-SPCA1 (XP_015137243.1); Dr-SPCA1 (XP_003200287). Hs: Homo sapiens; Pt: Pan troglodytes; Cl: Canis lupus; Mm: Mus musculus; Rt: Rattus norvegicus; Gg: Gallus gallus; Dr: Danio rerio

The resulting four SPCA1 protein isoforms differ in their C-terminal cytosolic tails and are organized in actuator domain (A), phosphorylation domain (P), nucleotide-binding domain (N), 5 stalk helices (S) in the cytoplasm, and 10 transmembrane helices (M) (Figure 1b).8 The C-terminal tails of each SPCA1 isoforms, unique to each alternatively spliced product (Figure 1c), present characteristics for potential specific functions that we will discuss later. The alternative splicing is not present in other species where we have a single SPCA1 (Figure 1c).

A schematic representation of the ATP2C1 gene sequence and the relative encoded SPCA1 protein sequences is reported in Figure 2. Here, we show where the exons start/finish (codons highlighted in yellow), which is the corresponding cytosolic (purple), transmembrane (gray) and luminal (blue) portion of SPCA1, as well as the C-terminal tail (azure).

Figure 2.

Figure 2

Figure 2

Figure 2

Identification of transmembrane domains vs cytosolic or luminal domains of SPCA1. For simplicity, SPCA1a (NP_055197) has been represented; other isoforms have identical sequence until the C-terminal tail. The highlighted codons in green and in red are the starting and stop codon, respectively. Highlighted in yellow is the first codon of each corresponding numbered exon. Highlighted in gray is the transmembrane domain. The highlighted amino acids in purple are cytoplasmic, whereas those highlighted in blue are luminal. The highlighted amino acids in azure represent the cytosolic C-terminal tail (underlined is the KXD/E motif putative COPI-binding site). The bold typed red and blue amino acids are the residues directly involved in the binding of Ca2+/Mn2+ and Mg2+, respectively. Of note, the putative COPI-binding motif KXD/E is just below the M10 domain. The prediction of these domains/residues was solved by similarity (UniProt database)

Hailey–Hailey Disease

Mutations of the ATP2C1 gene have been reported in Hailey–Hailey disease (HHD) patients,6, 7 originally described by the Hailey brothers (Hugh Edward and William Howard) in 1939.9 HHD is also known as familial benign chronic pemphigus10 or familial benign pemphigus.11 The prevalence of HHD is estimated to be 1:50 000.12 HHD is a monoallelic genetic disorder inherited in an autosomal dominant pattern,6, 7 meaning that one copy of the altered gene is sufficient to cause the disorder. Comparison between genotype and phenotype failed to show a clear correlation between the nature of the mutation and the clinical features of HHD (age of onset, severity, progression). Extensive inter-familial and intra-familial variation was noted in clinical features, as well as between families sharing the same mutation.13 Mutations in the ATP2C1 gene reduce the amount of functional SPCA1. This abnormality impairs cells ability to store Ca2+ normally. For unknown reasons, this abnormal Ca2+ storage affects keratinocytes more than other cells types. The abnormal regulation of Ca2+ impairs many cell functions, including cell adhesion. As a result, keratinocytes do not stick tightly to one another, which causes the epidermis to become fragile and less resistant to minor trauma. Because the skin is easily damaged, it develops raw, blistered areas, particularly in skin folds where there is moisture and friction.

Recent observations shed new light on a possible role for altered Ca2+ homeostasis and responsiveness in HHD keratinocytes in creating an early defect in differentiation process due to a reduced production of involucrin.14 Keratin expression was also delayed in acantholytic epidermal segments of HHD skin.15 Because of decreased Ca2+ stored in the lumen of the golgi apparatus of HHD keratinocytes, involucrin mRNA degraded in response to abnormally raised cytosolic Ca2+.16 From dermatological perspectives, the HHD patients have been treated with topical steroid preparations to help outbreaks. Several drugs (antibiotics, antifungals, corticosteroids, etc.) keep under control the progression of the disease but are ineffective for severe chronic or relapsing forms. Some HHD patients found relief in laser resurfacing that burns off the top layer of the epidermis, allowing healthy non-affected skin to regrow in its place.

Mutations on the Human ATP2C1 Gene

Here, we review the literature about the mutations occurring on the ATP2C1 gene, and give a comprehensive view of where these mutations fall along the gene sequence. Furthermore, we focus our attention on why some missense mutations affect SPCA1 efficiency without affecting the protein levels and address our interest to amino acidic residues that could probably have a role in the correct functioning of the protein and are not yet fully characterized. Finally, we focus our attention on the possible role of three different cytosolic tails of the SPCA1a, SPCA1b, and SPCA1d isoforms, and their potential for binding different partners.

Several mutations have been reported on the ATP2C1 gene in HHD patients, some of which were redundant even if no evident hotspots have been recognized so far. In Table 1 we summarize all the mutations reported so far, mentioning their localization along the gene sequence, the kind of mutation as well as the resultant change in the amino acid sequence. All the mutations generating truncated protein, which supposedly do not have a complete functionality or precise sub-organellar localization or are destabilized and therefore arguably destined for degradation, are indicated as premature termination codon (PTC).

Table 1. Mutations on the ATP2C1 gene reported in the literature.

Exon/Intron Nucleotide change Mutation Numbera Codonb Effect Domainc References
Exon 2 28delG/ins24bpd Deletion/insertion 1   PTC N-ter 6, 23 d
Exon 2d 115C>T Nonsense 4 R39X PTC N-ter/s1 6, 18, 19
Intron 2 117+2T>G Donor splice 1   PTC(?) N-ter/s1 95
Intron 2 118-2A>G Acceptor splice 1   PTC N-ter/s1 96
Intron 2 118-1G>A Acceptor splice 3     N-ter/s1 22 e,23, 97 d, f
Exon 3d 134delG Deletion 1 45GfsX1 PTC N-ter/s1 98
Exon 3 163C>T Nonsense 3 R55X PTC N-ter/s1 31, 97 d, f,99
Exon 3 168delC Deletion 1 ? PTC N-ter/s1 31
Exon 3 180G>Ad Nonsense 1 W60X PTC N-ter/s1 97
Exon 3 185delAGTT Deletion 1 62KfsX34 PTC N-ter/s1 28
Exon 3 212delT Deletion 1 71LfsX26 PTC M1 100g
Intron 3 235-2A>G Acceptor splice 2     M1 101, 102
Exon 5 335delT Deletion 1 111LfsX19 PTC M2 23
Intron 5 360+1G>A Donor splice 1     M2 33
Intron 5 360+1G>C Donor splice 1   Skip exon 5 M2 24
Intron 5 360+2T>A Donor splice 2   Skip exon 5 M2 103
Intron 5 361–1G>Ad Acceptor splice 1   PTC/skip exon 6 M2 19
Intron 5d 361-2A>Gd Acceptor splice 1   PTC/loss exon 6 M2 104
Exon 6 366T>A Nonsense 1 Y122X PTC M2 105
Exon 7 457C>T Nonsense 8 R153X PTC A 7, 20, 21, 23, 24, 25 e,106
Exon 7 490delT Deletion 1 163LfsX24 PTC A 13
Exon 7 519insA Insertion 2 173LfsX3 PTC A 13, 33
Exon 7 520delC Deletion 1 174RfsX14 PTC A 24
Intron 7 531+2T>Ad Donor splice 1     A 18
Exon 8 602C>Th Missense 2 P201Lh   A 6 d,13
Exon 8d 635C>A Nonsense 1 S212X PTC A 96
Exon 8 661A>Cd Missense 1 T221P   A 87
Exon 8 681dupA Insertion 1 227KfsX13 PTC A 24
Intron 8 688-1G>A Acceptor splice 1     A 13
Exon 9 689G>A Missense 1 G230D   A 107
Exon 9 705delA Deletion 1 235TfsX12 PTC A 108
Exon 9 745C>T Nonsense 1 Q249X PTC S3 13
Exon 10 767insCCCT Insertion 1 256TfsX42 PTC S3 7
Exon 10 775C>T Nonsense 1 Q259X PTC S3 105
Exon 10 806T>G Missense 1 L269R   M3 105
Exon 10 832G>Ai Missense/insertion 2 278GfsX22   M3 91
Intron 10 832+3A>T Donor splice 2     M3 13
Intron 10 832+2T>C Donor splice 1   Skip exon 10 M3 20
Intron 10d 833-1G>Ad Acceptor splice 1     M3 6
Exon 11 836insT Insertion 1 279IfsX19 PTC M3 7
Exon 11 854G>A Nonsense 1 W285X PTC l2 95
Intron 11 899+1G>T Donor splice 1   PTC M4 24
Intron 11 899+1G>C Donor splice 2   PTC M4 109
Exon 12 910G>T Missense 2 A304S   M4 7 j,20
Exon 12 920C>T Missense 1 P307L   M4 104
Exon 12 920C>A Missense 1 P307H   M4 36
Exon 12 923delAAG Deletion 1 308delEk   M4 28
Exon 12 925G>T Missense 1 G309C   M4 13
Exon 12 932del21bpd Deletion 1 311deld   M4 18
Exon 12 935T>C Missense 1 I312T   M4 110
Exon 12 950del9bp/ins24bpl Deletion/insertion 1 318-320del/insl   S4 20
Exon 12 953T>C Missense 1 L318P   S4 7
Exon 12 956delC Deletion 1 319AfsX3 PTC S4 24
Exon 12 1001delA Deletion 1 333KfsX12 PTC S4 13
Exon 12 1004T>C Missense 1 L335P   S4 111
Exon 12 1022T>C Missense 1 L341P   S4 13
Intron 12 1024+1G>Ad Donor splice 1   PTC/skip exon 12 S4 21
Exon 13 1031G>Ad, h Missense 1 C344Yd, h   P 6
Exon 13 1042T>C Missense 1 C348R   P 105
Exon 13 1045delT Deletion 1 348CfsX6 PTC P 13
Exon 13 1049A>T Missense 3 D350V   P 28
Exon 13 1055C>Td Missense 1 T352I   P 112
Exon 13 1058G>Td Missense 1 G353V   P 30
Exon 13d 1067delC Deletion 1 356TfsX3 PTC P 96
Exon 13 1068del16bpm Deletion 1 356TfsX60 PTC P 113
Exon 13 1085insA Insertion 1 363TfsX11 PTC P 29
Exon 13 1087A>G Missense 1 T363A   P 114
Exon 13 1089delTCAC Deletion 4 363TfsX21 PTC P 13, 23, 28, 115
Exon 14 1218G>Cd Missense 1 E406D Skip exon 14 P 19
Exon 15 1231T>C Missense 1 C411R   P 13
Exon 15d 1250G>Ad Missense 3 R417K   P 32
Intron 15 1308+1G>A Donor splice 1     P 36
Intron 15 1309-1G>A Acceptor splice 1     P 13
Intron 15 1309-4a>t/1309-2a>g Acceptor splice 1   Skip exon 16 P 7
Exon 16 1327C>Td Nonsense 1 Q443Xd PTC P 6
Exon 16 1388T>G Missense 1 V463G   P 20
Exon 16 1402C>T Nonsense 4 R468X PTC P 7, 26, 27, 28
Exon 16 1413G>C Missense 1 Q471H   ? 110
Intron 16 1415-2A>C Acceptor splice 1   PTC/skip exon 17 ? 104
Exon 17 1413del28bpn Deletion 2 472DfsX14 PTC ? 116
Exon 17 1431T>A Nonsense 1 C477X PTC ? 117
Exon 17 1455delAd Deletion 1 485QfsX1 PTC N? 118
Exon 17 1462deld,o Deletion 1 488delo   N 104
Exon 17 1469G>T Missense 1 C490F   N 31
Exon 17 1508delCTCAd Deletion 1 503TfsX32 PTC N 18
Exon 17 1510C>T Nonsense 1 Q504X PTC N 36
Exon 17 1516C>T Nonsense 4 Q506X PTC N 29, 30 d
Exon 17 1523delAT Deletion 2 508DfsX23 PTC N 97, 104
Exon 17 1566delCA Deletion 1 522LfsX9 PTC N 7
Intron 17 1570+2T>C Donor splice 1   PTC N 24
Exon 18 1582G>C Missense 1 A528P   N 23
Exon 18 1588G>C Missense 1 G530R   N 95
Exon 18 1685C>G Nonsense 3 S562X PTC N 6 d,13, 28
Exon 18 1709C>Td, h Missense 2 T570Id, h   N 6
Exon 18 1723delG Deletion 1 574QfsX24 PTC N 13
Exon 18 1738A>G Missense 2 I580V   N 13, 31
Intron 18 1694-1G>A Acceptor splice 1     N 6
Exon 19 1751T>C Missense 1 L584P   N 21
Exon 19 1782delAGTC Deletion 1 593SfsX5 PTC N 119
Exon 19 1816C>T Nonsense 1 Q606X PTC N 13
Intron 19 1839+2insTd Donor splice 1   PTC N 23
Intorn 19 1840-1G>C Acceptor splice 1     N 98
Exon 20 1854G>Ad Missense 1 R619K   N 87
Exon 20 1869delG Deletion 1 623RfsX2 PTC N 33
Exon 20 1874delA Deletion 1 M626X PTC N 120
Exon 20 1875delG Deletion 1 M626X PTC s5 7
Intron 20 1890+1delGTGAG/ins Donor splice 1     s5 22 e
Intron 20 1891-1G>T Acceptor splice 1     s5 121
Exon 21 1897C>T Nonsense 1 Q633X PTC s5 122
Exon 21 1914del/insd Deletion/insertion 1 638Vfs10X PTC s5 123 d
Exon 21 1922T>G Missense 1 M641R   s5 7
Exon 21d 1931A>G Missense 1 D644G   s5 33
Exon 21 1933G>A Missense 1 G645R   s5 7
Exon 21 1934G>Td Missense 1 G645V   s5 124
Exon 21 1942G>T Missense 1 D648Y   s5 104
Exon 21 1952C>A Missense 1 A651D   s5 105
Exon 21 1982T>G Missense 1 M661R   s5 113
Exon 21 1983delG Deletion 1 661MfsX14 PTC s5 7
Exon 21 2023delAd Deletion 1 675MfsX PTC s5 18
Exon 21 2025delG Deletion 1 675MfsX2 PTC s5 105
Intron 21d 2058(-17C>T)d Acceptor splice 1   PTC s5 97
Intron 21d 2058-1G>Cd Acceptor splice 1     s5 28
Intron 21 2058-1G>A Acceptor splice 1   Skip exon 22 s5 7
Exon 22 2068G>T Nonsense 1 E690X PTC s5 110
Exon 22 2111insA Insertion 1 704RfsX23 PTC M5 20
Exon 22 2126C>T Missense 3 T709M   M5 7, 28, 107
Intron 22 2127+1G>Ad Donor splice 2   Skip exon 23 (?) M5 28 d,125 d
Intron 22d 2126(+5G>A)d Donor splice 1   PTC M5 97
Exon 23 2132T>G Missense 1 I711R   M5 31
Exon 23 2141T>A Nonsense 1 L714X PTC M5 23
Exon 23 2164insACAT Insertion 1 722LfsX6 PTC l3 122
Exon 23 2198A>G Missense 1 Q733R   M6 31
Exon 23 2215delATT Deletion 1 739delI   M6 20
Exon 23 2224G>T Missense 1 D742Y   M6 13
Exon 23 2227delGd Deletion 1 743GfsX8 PTC M6 6
Exon 23 2231C>G Missense 2 P744R   M6 7 p,20
Exon 23 2235insC Insertion 1 746AfsX10 PTC M6 107
Exon 23 2236G>Ad Missense 1 A746Td   M6 18
Exon 23 2237C>Td Missense 1 A746V   M6 34
Intron 23 2243+2T>C Donor splice 1   PTC M6 104
Exon 24 2246T>G Missense 1 L749R   M6 20
Exon 24 2251delGT Deletion 1 751VfsX5 PTC s6 126
Exon 24 2264delA Deletion 2 755DfsX17 PTC s6 25, 33
Exon 24 2303delAC Deletion 2 768DfsX4 PTC s6 7, 20
Exon 24 2339delTTGTd Deletion 1 780LfsX3 PTC M7 19
Exon 24 2357delTT Deletion 1 786IfsX10 PTC M7 7
Exon 24 2365G>A Missense 1 G789R   M7 13
Exon 24 2371delTTGT Deletion 4 791LfsX12 PTC M7 7, 20, 127 d
Exon 24 2374delTTTG Deletion 10 792FfsX10 PTC M7 6 d,7, 13, 23, 31, 117, 128, 129 d,130
Exon 24 2375delTTGT Deletion 2 792FfsX4 PTC M7 102, 104
Exon 24 2384G>A Nonsense 1 W795X PTC l4 22 e
Exon 25 2395C>T Nonsense 14 R799X PTC l4 16 d,25, 31, 32, 33, 34 d
Exon 25d 2412delT Deletion 1 803IfsX7 PTC l4 102
Exon 25 2416C>T Nonsense 1 R806X PTC l4 13
Exon 25 2422delAC Deletion 2 808TfsX10 PTC l4 33
Exon 25 2445del10bp Deletion 3 814CfsX7 PTC M8 131
Exon 25 2454delT Deletion 1 818FfsX6 PTC M8 31
Exon 25 2454dupT Insertion 1 D819X PTC M8 28
Exon 25 2460delG Deletion 1 820MfsX4 PTC M8 21
Exon 25 2468A>Cd Missense 2 A823E   M8 97
Exon 26 2529delGT Deletion 1 843MfsX27 PTC M9 7
Exon 26 2558del10bpq Deletion 1 853MfsX17 PTC M9 31
Exon 26 2593C>Td Nonsense 2 Q865Xd PTC l5 6, 112
Exon 26d 2597A>C Missense 1 K866T   l5 96
Intron 26 2630-1delG Acceptor splice 2     M10 6 d,13
Exon 27 2660C>A Nonsense 1 S887X PTC M10 22e
Appendix 1
Exon 23 2130T>Cd Polymorphism 1 S710Sd   M5 87, 88
Appendix 2
Number Mutation % PTC %
59 Deletion/insertion 35.54 55 59.78
24 Nonsense 14.46 24 26.09
49 Missense 29.52 0 0.00
34 Acceptor/donor splice 20.48 13 14.13
166     92 55.42
Appendix 3
Normal                          
p.309 G G P I V V T V T L A L p.320
c.925 GGT CTC CCC ATT GTG GTC ACA GTG ACG CTA GCT CTT c.960
c.925 GGT CTC CTA GCT CTT c.939              
p.309 G L L A L p.313              
Mutant                          

Human ATP2C1 gene mutations were summarized. The mutations are grouped for deletion/insertion (azure), nonsense (orange), missense (yellow), acceptor/donor splice (green). Nucleotides are reported in italic along the table as well as in the figure legend and along the full manuscript. We found some reported mutations were inaccurate or not unified. Therefore, we revised or collated some descriptions according to the reported cDNA reference sequence (GenBank accession No. NM_AF181120).7

Appendix 1: A polymorphism was wrongly reported to be a new mutation 2323C>T generating Y711H.87 After careful check with the correct reading frame this was not a mutation but a polymorphism.88

Appendix 2: A resuming panel graphs the amount and relative percentage of each kind of mutations and PTC.

Appendix 3: The 884–904delCCATTGTGGTCACAGTGACGC mutation and consequent amino acid 296-302delIVVTVTL was incorrectly reported,18 while it referred to as a 21bp deletion located at 932-952 and amino acid 311-317delPIVVTVT. This mutation did not generate the reported missense mutation P295V;18 the first ‘C' of the codon 311 (encoding for a proline, P) recombined with ‘TA' of codon 318 (leucine, L) generating the codon CTA which encoded for a leucine.

a

Number of reported cases of patients presenting the mutation.

b

Missense mutations causing an amino acid substitution in extremely conserved residue through all the ATPases and in different species are highlighted in light pink.23

c

Putative protein domain prediction is based on the position of the equivalent residue within the structure of ATP2A1 (SERCA1).

d

Using the running correct coding sequence and relative reading frame of the ATP2C1 gene (Ref. NG_007379.1) we unified the position of the mutation site, protein change, exon/intron location all over the reported mutations. In doing this we found few mutations published as new which were already known.

e

The same authors published their findings in two identical papers on different journals.22, 89

f

Due to incorrect interpretation of discovered mutations the authors reported as new previously reported mutations.90

g

In their manuscript, the authors reported a previously described mutation. A mistake on referring to this mutation was recently reported (see erratum in Acta Derm Venereol 2015; 95: 1040).

h

P201L, C344Y, and T570I, respectively, represent mutations P185L, C328Y, and T554I, originally reported by Sudbrak et al.6 Mutation nomenclature has now been updated with respect to the 5'-end sequence published by Hu et al7 and the results of 5' RACE-PCR experiments from Fairclough et al.36

i

The missense mutation 832G>A causing the nucleotide change G278R generated an aberrant splicing with a resulting insertion of the first 11 bp (GTAAGAGAAGA) from intron 10 between the mutated exon10 and the exon 11 (see Figure 5 in Chao et al)91 causing a PTC.

j

This mutation was incorrectly reported as A304T by Hu et al7 as previously reported.20

k

E308, and not G309 (which are both Ca2+-binding site residue), was deleted.

l

950delCGCTAGCTCTT>CT>insCCACAATGTGTTGGTGTTATGAGAAT (underlined are the deleted/inserted nucleotides) generates the in frame 318delLAL/insTMCWCYEN.

m

1068delAAGAATGAAATGACTG.

n

The delGACAGACCAGAGATTTGTTTTATGAAAG cause a frame shift and PTC.

o

In frame delAAGTACTGTACTACATACCAGAGC with amino acid delKYCTTYQS.

p

This mutation was incorrectly reported as P724R by Hu et al7 as previously reported.20

q

The deleted sequence is TGGGACAATT.

After careful reviewing of literature using PubMed and the Chinese Biological Medicine Database (http://www.sinomed.ac.cn/zh/), we listed a total of 166 unique mutations on the ATP2C1 gene that have been reported in HHD to date. Of them, ~55% lead to PTC, supporting the possibility that haploinsufficiency of ATP2C1 is a prevalent mechanism for the dominant inheritance of HHD. Twenty-four (~14%) were nonsense mutations, fifty-nine (~36%) were deletion/insertion mutations (of which five (~4%) are in-frame deletion and insertion mutations), thirty-four (~20%) were splice-site mutations, and forty-nine (~30%) were missense mutations (Table 1). Thus, many mutations predict the absence, or a marked reduction of the mutated ATP2C1 product via nonsense-mediated mRNA decay. Non-conservative amino acid changes in functional domains of the molecule are highly conserved between golgi Ca2+ pumps from different species, and between other Ca2+-ATPases. In fact, some of these mutations occur at amino acid residues conserved between SPCA1 and SERCA1 (the ER ATPase Ca2+ pump type 1); the latter has previously been studied by site-directed mutagenesis and the relevant mutations were shown to abrogate SERCA1 function.17

Mutations are scattered along the ATP2C1 gene without apparent clustering, showing a substantial allelic heterogeneity, and are distributed all over the encoded sequence (Supplementary Figure 1), as well as in the intron splice sites generating alternative splicing and/or truncated proteins. Mutations affect all domains of the resulting protein. Rarely, mutations seem to be addressed to the 3′ end of the gene (namely the last 3 exons/introns), where the alternative splicing generates the four different isoforms of SPCA1.

Few nonsense mutations were frequently reported in different families worldwide (reports with at least three cases): 115C>T causing R39X;6, 18, 19 457C>T causing R153X;7, 20, 21, 22, 23, 24, 25 1402C>T causing R468X;7, 26, 27, 28 1516C>T causing Q506X;29, 30 and 2395C>T causing R799X.18, 25, 31, 32, 33, 34 The above single residues represent ‘hotspots' for mutations, and notably, they all occur at CpG sites where the possibility of mutations is higher.35 The fact that the majority of the mutations cause PTC through frameshift or single-base-pair substitution points to haploinsufficiency as the prevalent mechanism for the dominant inheritance of HHD.6, 7 However, the possibility that at least some mutations cause the disease through a dominant negative mechanism cannot be excluded.13

Interestingly, only one mutation was found in the most 3′ region (exons 27–28) of the gene where differential splicing generates the four different transcripts.22 The single reported mutation, located in exon 27, was a nonsense mutation (2660C>A), which results in a stop codon (S887X) on the last transmembrane domain (M10). The mutation was found in a patient with a family history of HHD and suffering from classical HHD symptoms.22 Notably, this mutation caused the loss of the C termini of the SPCA1a, SPCA1b and SPCA1d isoforms but not of SPCA1c that does not include exon 27. Thus, SPCA1c, the shortest of the isoforms, misses the M10, and therefore, its stability and consequent ability to functionas a Ca2+ pump is rather questionable.36 Nevertheless, if SPCA1c was effectively expressed, we can conclude that it is not functional enough to overcome the loss of the other three isoforms at least in the skin of the patient presenting the mentioned S887X mutation.22 Remarkably, this observation suggests that the mRNA encoding for SPCA1c is probably not translated as previously suggested.37

Furthermore, the mutation on exon 27 causes a reduction in SPCA1a, SPCA1b and SPCA1d of 33, 52 and 63 amino acids, respectively, resulting in a partial truncation of the M10 and of the full cytoplasmic tail, similarly to what happens in SPCA1c (888 amino acids). Of consequence, this mutation is predicted to determine an incomplete expression and degradation of these SPCA1 isoforms thus resembling SPCA1c. Hereafter, we will no more consider SPCA1c in this discussion.

Splice variants differ in their C-terminal tail sequence (Figure 1c) and this is likely to be important for the functionality of the pump. Indeed, the C-terminal tail could have a role in mediating interactions with cytoplasmic effectors for intracellular signaling or for targeting the single isoforms to specific sub-organellar localization. Presently, no cytoplasmic interacting proteins have been found for the SPCA1 C-terminal domain. However, specific interactions of different SPCA1 tails with proteins involved in membrane trafficking (i.e., golgi matrix, Ca2+-binding proteins, Arf/Rab family members, cytoskeleton, etc.) could support a specific role for C-terminal tail in the differential distribution of the protein at sub-organellar level. This would in turn make them unique not only in triggering the Ca2+ influx into the golgi apparatus, but also in mediating different cytoplasmic signaling, thus orchestrating membrane trafficking at different levels along the secretory pathway. Obviously, these speculations need to be experimentally proven.

No further mutations have been discovered in the 3′-end of the ATP2C1 gene. In other words, once the ATP2C1 gene is mutated (independently if missense, nonsense, insertion and/or duplication or part of the primary sequence) the functionality of all the isoforms is equally compromised in HHD patients, and at least in the skin, levels of SPCA1 appear to be not sufficient. However, up-regulation of SERCA2 (the ER ATPase Ca2+ pump type 2) has been recently shown to (at least partly) compensate for the decreased levels of SPCA1 in HHD.38

Therefore, although SPCA1 is ubiquitously expressed, is there differential expression of the isoforms? Is the compensatory role for non-functional or depleted SPCA1 by other pumps tissue specific? Is there a general mechanism? If so, how does it work? Even if some tentative explanations have been given,38, 39 these open questions need answers to fully understand the role and distribution of the SPCA1 isoforms.

Missense Mutations on the ATP2C1 Gene

Missense mutations generate single amino acid substitution, not leading to a PTC. A quick view on where the missense mutations occur along the ATP2C1 gene sequence gives an idea of their preferential distribution in few exons. In particular, almost two-thirds (63%) of the missense mutations (31/49) localize in only five exons (exon 12, 13, 18, 21, and 23; Table 1). These exons encode for M4, P, ATP and M5/M6 domains, respectively (Figure 3). Amino acids located on M4, M5 and M6 (together with M8) transmembrane domains are critical for Ca2+/Mn2+ binding. It is not surprising that affecting residues in these regions, either directly involved in Ca2+-binding or compromising the stability or structure of the protein, may cause a severe effect on SPCA1 functionality, also without a reduction in its levels. Looking at the conservation across species we found high level of homology of these exons and conservativeness of the resulting amino acid coded by the codons where missense mutations occur (Figure 3), confirming their critical role.

Figure 3.

Figure 3

Missense mutations mostly affect critical SPCA1 domains. Most of the missense mutations localize on exons 12, 13–16, 18, 21, and 23 of ATP2C1 gene coding for the indicated protein domains (M4, P, N, S5, M5-M6) crucial for the protein enzymatic activity and Ca2+/Mn2+ binding. In human HHD patients the missense mutations cause the indicated amino acid changes, supporting a crucial role for them in functionality of the SPCA1. Of note, the mutations localize on highly conserved residue/codon between the considered species, highlighting the importance of those encoded amino acids. In blue are indicated the different amino acids compared to the human sequence, in red where the mutations occur. Alignments were obtained from Ensembl database as described in Figure 1

Several residues have been reported to have a critical and direct role in Ca2+/Mn2+ binding, which are conserved throughout species40 and also in SPCA2, the homolog of SPCA1.41 Missense mutation D778A in the yeast homolog (PMR1) resulted in a loss of function mutant apparently defective for the transport of both Ca2+ and Mn2+, whereas mutant Q783A displayed a differential sensitivity consistent with the selective loss of Mn2+ transport.42 In a similar study, G783 and V335 in PMR1 showed conformation-sensitive packing at the cytoplasmic interface, suggesting that these residues are important in organizing the entry gate for Mn2+ ions.43 Missense mutation can also cause a change in protein conformation affecting possible interaction of SPCA1 with other proteins, like cofilin, which has been found to be crucial in recruiting actin to mediate the cargo sorting that interact directly with SPCA1 nucleotide domain through an interaction mediated by Ca2+ ions.44

Remarkably, these examples highlight how a possible missense mutation can affect SPCA1 resulting not only in a less efficient pump, but also accounting for its diminished ability to interact with other proteins. In some HHD patients this scenario results in a severe etiology, comparable to the situation where mutations on ATP2C1 gene cause PTC, but in the presence of unaffected levels of total protein expression.

ATP2C1 Gene: Human Versus Murine

Another aspect to highlight is the different etiology occurring between humans and mice as a consequence of ATP2C1 mutations. In humans, HHD rarely degenerates in skin cancer although squamous cell carcinoma and basal cell carcinoma arising in lesions of HHD have been described in the literature.45, 46, 47 However, which is the relationship, if any, between skin cancer development and HHD has not been deeply investigated. To our knowledge, there are no reports of melanoma or non-cutaneous malignant neoplasms associated with HHD.

On the other side, heterozygotic mice exhibit no evidence of skin lesions indicative of HHD, meanwhile generated skin cancer in adult.48, 49 Null mutant embryos exhibited growth retardation, failure of neural tube closure, but normal hematopoiesis and cardiovascular development, resulting in embryonic lethality.48 At subcellular level, golgi membranes of Spca1−/− embryos were dilated, had fewer stacked leaflets, and were expanded in amount, consistent with increased golgi biogenesis.48 Increased golgi-associated vesicles and a marked reduction of ribosomes on rough ER were also observed.48 Coated pits, junctional complexes, desmosomes, and basement membranes appeared normal in mutant embryos, indicating that processing and trafficking of proteins in the secretory pathway was not massively impaired.48 However, apoptosis was increased, possibly the result of secretory pathway stress, and a large increase in cytoplasmic lipid was observed in mutant embryos, consistent with impaired handling of lipids by the golgi.48 Possibly, reduction of the proper levels of Spca1 resulted in alteration in the activity of the glycosyl-transferases due to a decreased accumulation of Mn2+ in the golgi lumen, which could contribute to the secretory pathway stress as well as apoptosis due to a decreased of Ca2+ handling.

Recently, an important difference between human and murine genomes that could explain the differential outcome of mutations in the two species has been reported.50 The Atp2c1 gene in mice expresses only one isoform of the gene, not presenting alternative splicing events at the 3′-end of the gene like the human counterpart. The last exon of the ATP2C1 human gene overlapped in the antisense direction with the last exon of the ASTE1 (also named HT001) gene, which codes for a protein of unknown function.50 ATP2C1/ASTE1 overlap (not present in the murine genome) could have a role in regulating isoform expression, or more largely, the full SPCA1 expression.50 This sort of regulation could have in turn a protective role that is imbalanced once one of the two alleles is mutated in humans, whereas not in mice.50

Putative Interacting Domains in the C-terminal Cytosolic Tails of SPCA1 Isoforms

As suggested above, different SPCA1 isoforms due to their unique C termini could have a different pattern of distribution and functional roles. The primary sequence of the C-terminal tail of each isoform is reported in Figure 1c. An intriguing possibility is that the uniqueness of their function is a consequence of the interaction with different protein partners. It is well known that many resident proteins display in their tails, motifs like sorting signals responsible for retrieval or retention. For instance, the C-terminal KKXX motif, identified in many ER-localized type I membrane proteins, can function as an ER-retention signal to retrieve ER-resident membrane proteins from the golgi via a direct interaction with coat protein complex I (COPI) coatomer.51, 52, 53 Another example is the semi-conserved (F/L)-(L/V)-(S/T) motif, which has been shown to function as a golgi-retention signal by interacting with COPI vesicles via Vps74p and thereby maintaining the steady golgi localization of glycosyl-transferases in yeast.54 Recently, a conserved retention function and COPI-binding ability for the KXD/E motif has been shown in the golgi apparatus through the evolution in different species and in many endomembrane proteins.55, 56

Using bioinformatics tools (see Figure 4 legend), we analyzed the SPCA1 sequences in the areas corresponding to the terminal exons 26–28 in terms of secondary structure propensity (Figure 4a), predicted transmembrane helices topology (Figure 4b), and interaction with putative protein partners (Figure 4c). We found that the KXD/E motif is present in isoforms SPCA1a, SPCA1b, and SPCA1d, in the cytosolic tail immediately after the M10 (Figure 4c) in a region that is predicted to be a helical extension of M10 in all three isoforms (compare Figures 4a and b). This motif is also highly conserved throughout different species suggesting functional importance (Figure 4d).

Figure 4.

Figure 4

Bioinformatics analysis of SPCA1 isoforms C-terminal region. (a) Secondary structure propensities in the proteins' regions encoded by terminal exons were predicted with the program PSIPRED.92 Highlighted in pink is the corresponding sequences in the KXD/E motif. Predictions indicate that this motif is located in a helical extension spanning outside transmembrane helix M10 (see also b). Interestingly this helix is predicted to have different length in the three isoforms where it is present (a, b and d). (b) Transmembrane topology prediction was performed using the algorithms MEMSAT3 (ref. 93) and TMHMM2 (http://www.cbs.dtu.dk/services/TMHMM) yielding very similar results. In the isoforms SPCA1a, SPCA1b and SPCA1d, two transmembrane helices are predicted by both algorithms, the first (M9) with cytosolic-lumenal orientation and the second (M10) with opposite orientation. In the SPCA1c isoform a single cytosolic-lumenal transmembrane helix (M9) is predicted. Shown are results from MEMSAT3 where ‘+' stands for cytosolic residue, ‘−' for lumenal residue and I, X and O for transmembrane residues (I close to cytosolic, X central and O close to lumenal). (c) The MoRFPred algorithm94 was used to predict, in the different isoforms, regions of the protein that are prone to interact with protein partners, due to disorder-to-order transitions, here highlighted in red. The EDSCV motif found at the C-terminal of isoforms b and d matches the consensus sequence specifically recognized by class I PDZ domains. The other regions predicted in isoforms ‘a' and ‘d' may be recognized by unknown protein partners. Highlighted in red are the putative residues of binding motifs. (d) The exon 27 encoding for most of the M10 domain and the C-terminal tail where putative binding motifs are located. The KXD/E is highly conserved. Sequence of Homo sapiens was compared to the four species of mammals chosen (Ensembl database. ID: Homo Sapiens ATP2C1-011 ENST00000428331; Pan troglodytes ATP2C1-201 ENSPTRT00000028742; Canis lupus ATP2C1-201 ENSCAFT00000031759; Mus musculus ATP2C1-005 ENSMUST00000038118; Rattus norvegicus ATP2C1-201 ENSRNOT00000018175) and two non-mammalian (Ensembl database. ID: Gallus gallus ATP2C1-201 ENSGALT00000018903; Danio rerio ATP2C1-001 ENSDART00000084528)

Therefore, SPCA1 is potentially involved in the interaction with COPI. This reinforces the idea that SPCA1 could be involved in regulating local fusion/fission of cargo domain/vesicles carrying proteins along the secretory pathway, triggering the cytosolic Ca2+ level in the peri-golgi membranes, where Ca2+-binding proteins are temporarily recruited to organize and regulate the membrane fusion/fission, a fundamental process for cargo progression.4, 57

The analysis of the potential of C-terminal tail residues to interact with protein partners also highlighted additional sequences, which are differentially present in the four isoforms (Figure 4c). In particular, the isoforms SPCA1b and SPCA1d both end with the C-terminal sequence EDVSCV, which is predicted to be a protein interaction site (Figure 4c). By inspecting the literature we realized that this motif perfectly reproduces the structural features that are necessary for recognition by class I PDZ domains: (i) being at the C-terminal of a protein and (ii) matching the consensus for the last three residues S/T-X-Φ-COO−,58 where X is any residue and Φ is a hydrophobic residue (often a valine). Thus, this motif is strongly predicted to interact with the PDZ domains of other proteins.59 Several proteins containing the PDZ domain can potentially interact with the tail of SPCA1b and SPCA1d modulating the function of the pump. Interestingly, evidences that the C-terminal tail of SPCA1 could interact with the golgi matrix arise from a recent observation of the interaction of C-terminal valine-bearing cargoes moving through the golgi apparatus by binding to GRASP55 and GRASP65, two golgi matrix proteins that contain PDZ domains.60 PDZ domain recognition of the C-terminal tail is involved in golgi maintenance and in cargo progression.60, 61 The SPCA1 isoforms present a valine residue as last amino acid residue in the C-terminal position (Figures 1c and 4c).

Also the FLEV motif present at the C-terminal end of SPCA1a and in the cytoplasmic tail of SPCA1d is predicted to be a protein binding motif (Figure 4c). Interestingly, this motif is also present in rat calsequestrin (CASQ; AAA75480). CASQ regulates Ca2+-binding in the sarcoplasmic reticulum in cardiac muscle cells. However, this domain is not conserved between the human and murine proteins. This unique feature of the human protein could favor specific protein interactions by SPCA1 isoforms to mediate signaling and trigger the modulation of Ca2+ levels in the interested subcellular compartment. In the case of CASQ the interactors could be triadin and junctin.62 Analogs could have the same role in the golgi apparatus for SPCA1, working as Ca2+-mediated sensing probes to regulate the pump activity.

The above observations reinforce the hypothesis for a functional role of each different C-terminal tail in mediating interaction with different proteins.

Importance of SPCA1 in Membrane Trafficking: What is the Possible Role of each Isoform?

In addition to the maintenance of intra-golgi Ca2+ and Mn2+, which has direct effects on Ca2+-dependent proteases63 and Mn2+-dependent glycosyltransferases64 (see also below), there is also evidence that SPCA1 may affect cytosolic Ca2+ signaling.65, 66, 67, 68, 69 Ca2+ released from the golgi leads to a localized increase in cytosolic Ca2+ that stimulates vesicle fusion, thus contributing to intra-golgi transport of cargo,70 consistent with the distribution of SPCA1 in the golgi apparatus.4 Thus, maintenance of luminal Ca2+ stores by SPCA1 may enable Ca2+ signaling events that directly affect the transport of cargo-containing domains from ER to the golgi apparatus and from there to their final destinations.3 If so, a deficiency in this signaling function likely contributes to the mislocalization of proteins in response to a decreased SPCA1 activity/level.71, 72, 73

Furthermore, effects on the ER were also observed in mammalian cells. Depletion of SPCA1 affected degradation of a mutant glycoproteins via ERAD, although it did not affect degradation of a non-glycoprotein substrates.71 Signaling pathways that mediate ER stress responses were intact and functional; however, SPCA1-deficient cells were highly sensitive to treatment with tunicamycin or thapsigargin, both of which cause ER stress and activate ER stress responses.71 Evidences of golgi stress, secondary effects on the ER, and stress responses were categorized as survival responses or apoptotic responses.72

Although the role of SPCA1 in the Ca2+ homeostasis of the golgi apparatus and its role in membrane trafficking has been well described and accepted,70, 73 the role of single isoforms still needs to be investigated. Possible differential distribution along the secretory pathway at sub-organelle level as well as at tissue level remains completely uninvestigated too. SPCA1 isoforms differ from each other in their C-terminal tails that is not directly involved in the regulation of Ca2+-binding. However, many Ca2+-binding proteins are recruited on the golgi membranes during the trafficking pulse (cPLA2, calmodulin, SNARE cofactors, etc.).3 These proteins are recruited on the golgi membranes through a local release of Ca2+ from the golgi apparatus and they should be released as soon as they fulfill their own function.3 The recruited Ca2+-binding proteins are addressed to the so-called lateral rims (or non compact zones) of the golgi stacks and in both the cis- and trans-golgi area where SPCA1 is clearly localized.4 Whether SPCA1 C terminus tails are involved in establishing temporary contacts with Ca2+-binding recruited proteins remains unknown.

SPCA1 is also able to transport Mn2+ ions into the golgi with high affinity, an ability that SERCAs do not possess. As Mn2+ is not used for signaling like Ca2+, the main reason for removing it from the cytosol is to prevent Mn2+ toxicity.74 Several proteins within the pathway require either Ca2+ and Mn2+, or other divalent ions to function as metal cofactors, such as amino-peptidase P,75 pro-protein convertases76 and sulfotransferarese.77 Even if there is no differential efficiency in the removal of ions by each SPCA1 isoform, potential differential sub-organellar localization of the isoforms may reflect the pump activity involved in different Ca2+/Mn2+-dependent pathways.

The inefficient removal of Ca2+/Mn2+ from the cytosol by SPCA1, with consequent decreased accumulation in the golgi, causes alteration in intracellular signaling and post-transcriptional protein modifications. Mn2+ is a fundamental cofactor of the golgi resident enzymes mannosidases.78 Reduced removal of Ca2+ from the cytosol during the arrival and the passage of cargo proteins to and through the golgi apparatus, significantly reduces physiological protein secretion.4

Furthermore, SPCA1 seems to have a direct role in organizing the cargo sorting at the trans-golgi network79, 80 and subsequent departure.81 Functional SPCA1 is important for insulin-like growth factor receptor (IGF1R) processing in basal-like breast cancer, and inhibition of SPCA1 ‘may offer an alternative strategy to direct inhibitors of IGF1R and attenuate the processing of other proprotein convertase substrates…'.82 However, which of the SPCA1 isoforms, if any, works at this level still needs to be defined.

Membrane Trafficking in HHD Keratinocytes

In the skin of HHD patients, one of the altered clusters of proteins affected by non-functional or depleted SPCA1 are the adhesion proteins. The loss of one functional copy of the ATP2C1 gene in HHD is characterized by the development of skin lesions and an associated loss of cell–cell adhesion.6, 7 Proteins necessary for desmosome formation (as well as extracellular matrix components) are likely to be directly involved in cellular interactions and are affected in SPCA1+/− cells.83 Desmosomes are molecular complexes of cell adhesion proteins and linking proteins that attach the cell surface adhesion proteins to intracellular keratin cytoskeletal filaments. Desmoglein and desmocollin, two components of the desmosome, are members of the cadherin family of cell adhesion molecules. They are transmembrane proteins that bridge the space between adjacent epithelial cells by way of homophilic binding of their extracellular domains to other desmosomal cadherins on the adjacent cell.83 Both have five extracellular domains and have Ca2+-binding motifs. Defects in anchoring to cytoskeletal constituents can also reflect possible intracellular morphological defects as observed in golgi apparatus.84

Another important finding relating SPCA1 depletion and protein secretion in keratinocytes comes from a study on involucrin (a protein that makes up the cornified envelope of keratinocytes and is expressed in response to increased cytosolic Ca2+).14 Involucrin is expressed at lower levels in cells from HHD patients or cells treated with SPCA1 RNAi when compared to normal keratinocytes.14 Decreased level of involucrin was caused by lower involucrin mRNA levels in HHD keratinocytes; decreased involucrin mRNA, in turn, was caused by increased rates of involucrin mRNA degradation.14 Ca2+-sensitive involucrin AP-1 promoter activity was increased, both in HHD keratinocytes and in RNAi experimental model, suggesting compensatory promoter up-regulation in the face of increased mRNA degradation.14 Thus, transport/secretion of desmosomes components are impaired by SPCA1 depletion.

Further observations revealed that claudins are also regulated by SPCA1.85 Claudins are a family of proteins that are the most important components of the tight junctions, establishing a barrier that controls the flow of molecules in the intercellular space between the cells of an epithelium. In SPCA1-depleted keratinocytes protein levels of components of desmosomes, adherens and tight junctions did not show marked changes except for claudin1 and 4 that were increased.85

Whether and which SPCA1 isoforms are implicated in the regulation of specific cell adhesion protein trafficking is unknown. Nevertheless, the reason why desmosomes/tight junctions are affected more in the skin than in other epithelial tissues has to be investigated.

Conclusions

Distribution of SPCA1 isoforms along the secretory pathway in different cell types could lead to a better understanding of which isoform is doing what, when, and where. Considering that SPCA1 is ubiquitously expressed, the fundamental role of this protein in regulating the Ca2+/Mn2+ physiology86 and membrane trafficking in different cell types/tissues could be due to specific clusters of SPCA1 isoforms. Further investigations to clarify the role of each SPCA1 isoforms will benefit the understanding of the biology of secretion in health and disease, and will impact on several pathological conditions.

Acknowledgments

Thanks to Dr Seetharaman Parashuraman, Institute of Protein Biochemistry, Naples, Italy for critical reading of the manuscript. This work was partly supported by a grant from the AIRC Associazione Italia Ricerca sul Cancro (IG-2014 15197 to LF).

Glossary

CASQ

calsequestrin

COPI

coat protein complex I

HHD

Hailey–Hailey disease

IGF1R

insulin-like growth factor receptor

ER

endoplasmic reticulum

PMR1

the yeast homolog of SPCA1

SERCA

ER ATPase Ca2+ pump type 2

SPCA1

secretory pathway Ca2+-ATPase pump type 1

TGN

trans-Golgi network

The authors declare no conflict of interest.

Footnotes

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)

Edited by E Candi

Supplementary Material

Supplementary Figure 1

References

  1. De Matteis MA, Luini A. Exiting the golgi complex. Nat Rev Mol Cell Biol 2008; 9: 273–284. [DOI] [PubMed] [Google Scholar]
  2. Brandizzi F, Barlowe C. Organization of the ER–golgi interface for membrane traffic control. Nat Rev Mol Cell Biol 2013; 14: 382–392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Micaroni M. Calcium around the golgi apparatus: implications for intracellular membrane trafficking. Adv Exp Med Biol 2012; 40: 439–460. [DOI] [PubMed] [Google Scholar]
  4. Micaroni M, Perinetti G, Berrie CP, Mironov AA. The SPCA1 Ca2+-pump and intracellular membrane trafficking. Traffic 2010; 11: 1315–1333. [DOI] [PubMed] [Google Scholar]
  5. Wootton LL, Argent CC, Wheatley M, Michelangeli F. The expression, activity and localisation of the secretory pathway Ca2+-ATPase (SPCA1) in different mammalian tissues. Biochim Biophys Acta 2004; 1664: 189–197. [DOI] [PubMed] [Google Scholar]
  6. Sudbrak R, Brown J, Dobson-Stone C, Carter S, Ramser J, White J et al. Hailey–Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca2+ pump. Hum Mol Genet 2000; 9: 1131–1140. [DOI] [PubMed] [Google Scholar]
  7. Hu Z, Bonifas JM, Beech J, Bench G, Shigihara T, Ogawa H et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey–Hailey disease. Nat Genet 2000; 24: 61–65. [DOI] [PubMed] [Google Scholar]
  8. Matsuda M, Hamada T, Numata S, Teye K, Okazawa H, Imafuku S et al. Mutation-dependent effects on mRNA and protein expressions in cultured keratinocytes of Hailey–Hailey disease. Exp Dermatol 2014; 23: 509–528. [DOI] [PubMed] [Google Scholar]
  9. Hailey H, Hailey H. Familial benign chronic pemphigus. Report of 13 cases in four generations of a family and report of 9 additional cases in 4 generations of a family. Archiv Dermatol Syphilol 1939; 39: 679–685. [Google Scholar]
  10. James W, Berger T, Elston D Andrews' Diseases of the Skin: Clinical Dermatology, 10th edn. Saunders: Philadelphia, PA, 2005. [Google Scholar]
  11. Freedberg IM, Goldsmith LA, Katz S, Austen F, Wolff K Fitzpatrick's Dermatology in General Medicine, 6th edn. McGraw-Hill: New York, NY, 2003. [Google Scholar]
  12. Foggia L, Hovnanian A. Calcium pump disorders of the skin. Am J Med Genet C Semin Med Genet 2004; 131C: 20–31. [DOI] [PubMed] [Google Scholar]
  13. Dobson-Stone C, Fairclough R, Dunne E, Brown J, Dissanayake M, Munro CS et al. Hailey–Hailey disease. molecular and clinical characterization of novel mutations in the ATP2C1 gene. J Invest Dermatol 2002; 118: 338–343. [DOI] [PubMed] [Google Scholar]
  14. Aberg KM, Racz E, Behne MJ, Mauro TM. Involucrin expression is decreased in Hailey–Hailey keratinocytes owing to increased involucrin mRNA degradation. J Invest Dermatol 2007; 127: 1973–1979. [DOI] [PubMed] [Google Scholar]
  15. Bergman R, Levy R, Pam Z, Lichtig C, Hazaz B, Friedman-Birnbaum R. A study of keratin expression in benign familial chronic pemphigus. Am J Dermatopathol 1992; 14: 32–36. [DOI] [PubMed] [Google Scholar]
  16. Su MJ, Bikle DD, Mancianti ML, Pillai S. 1,25-Dihydroxyvitamin D3 potentiates the keratinocyte response to calcium. J Biol Chem 1994; 269: 14723–14729. [PubMed] [Google Scholar]
  17. Rice WJ, MacLennan DH. Scanning mutagenesis reveals a similar pattern of mutation sensitivity in transmembrane sequences M4, M5, and M6, but not in M8, of the Ca2+-ATPase of sarcoplasmic reticulum (SERCA1a). J Biol Chem 1996; 271: 31412–31419. [DOI] [PubMed] [Google Scholar]
  18. Chao SC, Tsai YM, Yang MH. Mutation analysis of ATP2C1 gene in Taiwanese patients with Hailey–Hailey disease. Br J Dermatol 2002; 146: 595–600. [DOI] [PubMed] [Google Scholar]
  19. Btadini W, Abou Hassan KO, Saadeh D, Abbas O, Ballout F, Kibbi AG et al. Identification of several mutations in ATP2C1 in Lebanese families: insight into the pathogenesis of Hailey–Hailey disease. PLoS One 2015; 10: e0115530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ikeda S, Shigihara T, Mayuzumi N, Yu X, Ogawa H. Mutations of ATP2C1 in Japanese patients with Hailey–Hailey disease: intrafamilial and interfamilial phenotype variations and lack of correlation with mutation patterns. J Invest Dermatol 2001; 117: 1654–1656. [DOI] [PubMed] [Google Scholar]
  21. Yokota K, Takizawa Y, Yasukawa K, Kimura K, Nishikawa T, Shimizu H. Analysis of ATP2C1 gene mutation in 10 unrelated Japanese families with Hailey–Hailey disease. J Invest Dermatol 2002; 118: 550–551. [DOI] [PubMed] [Google Scholar]
  22. Li H, Sun HK, Zhu XJ. Four novel mutations in ATP2C1 found in Chinese patients with Hailey–Hailey disease. Br J Dermatol 2003; 149: 471–474. [DOI] [PubMed] [Google Scholar]
  23. Fairclough RJ, Lonie L, Van Baelen K, Haftek M, Munro CS, Burge SM et al. Hailey–Hailey disease: identification of novel mutations in ATP2C1 and effect of missense mutation A528P on protein expression levels. J Invest Dermatol 2004; 123: 67–71. [DOI] [PubMed] [Google Scholar]
  24. Hamada T, Fukuda S, Sakaguchi S, Yasumoto S, Kim SC, Hashimoto T. Molecular and clinical characterization in Japanese and Korean patients with Hailey–Hailey disease: six new mutations in the ATP2C1 gene. J Dermatol Sci 2008; 51: 31–36. [DOI] [PubMed] [Google Scholar]
  25. Cialfi S, Oliviero C, Ceccarelli S, Marchese C, Barbieri L, Biolcati G et al. Complex multipathways alterations and oxidative stress are associated with Hailey–Hailey disease. Br J Dermatol 2010; 162: 518–526. [DOI] [PubMed] [Google Scholar]
  26. Szigeti R, Chao SC, Várszegi D, Czakó M, Kosztolányi G, Kellermayer R. The first genetically supported case of chronic benign pemphigus Hailey–Hailey disease in Hungary. Orv Hetil 2005; 146: 1933–1935. [PubMed] [Google Scholar]
  27. Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey–Hailey disease. J Invest Dermatol 2006; 126: 229–231. [DOI] [PubMed] [Google Scholar]
  28. Cheng TS, Ho KM, Lam CW. Heterogeneous mutations of the ATP2C1 gene causing Hailey–Hailey disease in Hong Kong Chinese. J Eur Acad Dermatol Venereol 2010; 24: 1202–1206. [DOI] [PubMed] [Google Scholar]
  29. Racz E, Csikos M, Karpati S. Novel mutations in the ATP2C1 gene in two patients with Hailey–Hailey disease. Clin Exp Dermatol 2005; 30: 575–577. [DOI] [PubMed] [Google Scholar]
  30. Zhang XQ, Wu HZ, Li BX, Xu YS, Wu JB, Lin LL et al. Mutations in the ATP2C1 gene in Chinese patients with Hailey–Hailey disease. Clin Exp Dermatol 2006; 31: 702–705. [DOI] [PubMed] [Google Scholar]
  31. Zhang HZ, Tian HQ, Du DH, Wang GJ, Yan XX, Liu H et al. Analysis of ATP2C1 gene mutations in Chinese patients with Hailey–Hailey disease. Clin Exp Dermatol 2012; 37: 190–193. [DOI] [PubMed] [Google Scholar]
  32. Zhang D, Li X, Xiao S, Huo J, Wang S, Zhou P. Detection and comparison of two types of ATP2C1 gene mutations in Chinese patients with Hailey–Hailey disease. Arch Dermatol Res 2012; 304: 163–170. [DOI] [PubMed] [Google Scholar]
  33. Majore S, Biolcati G, Barboni L, Cannistraci C, Binni F, Crisi A et al. ATP2C1 gene mutation analysis in Italian patients with Hailey–Hailey disease. J Invest Dermatol 2005; 125: 933–935. [DOI] [PubMed] [Google Scholar]
  34. Nemoto-Hasebe I, Akiyama M, Osawa R, Nakamura H, Shimizu H. Diagnosis of Hailey–Hailey disease facilitated by DNA testing: a novel mutation of ATP2C1. Acta Derm Venereol 2008; 88: 399–400. [DOI] [PubMed] [Google Scholar]
  35. Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 2012; 488: 471–475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Fairclough RJ, Dode L, Vanoevelen J, Andersen JP, Missiaen L, Raeymaekers L et al. Effect of Hailey–Hailey disease mutations on the function of a new variant of human secretory pathway Ca2+/Mn2+-ATPase (hSPCA1). J Biol Chem 2003; 278: 24721–24730. [DOI] [PubMed] [Google Scholar]
  37. Dode L, Andersen JP, Raeymaekers, Missiaen L, Vilsen B, Wuytack F. Functional comparison between secretory pathway Ca2+/Mn2+-ATPase (SPCA) 1 and sarcoplasmic reticulum Ca2+-ATPase (SERCA) 1 isoforms by steady-state and transient kinetic analyses. J Biol Chem 2005; 280: 39124–39134. [DOI] [PubMed] [Google Scholar]
  38. Zhang D, Li X, Wang Z, Zhang Y, Guo K, Wang S et al. Hailey–Hailey disease: investigation of a possible compensatory SERCA2 up-regulation and analysis of SPCA1, p63, and IRF6 expression. Arch Dermatol Res 2015; 307: 143–149. [DOI] [PubMed] [Google Scholar]
  39. Missiaen L, Dode L, Vanoevelen J, Raeymaekers L, Wuytack F. Calcium in the golgi apparatus. Cell Calcium 2007; 41: 405–416. [DOI] [PubMed] [Google Scholar]
  40. Mukhopadhyay S, Linstedt AD. Identification of a gain-of-function mutation in a golgi P-type ATPase that enhances Mn2+ efflux and protects against toxicity. Proc Natl Acad Sci USA 2011; 108: 858–863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Shull GE, Okunade G, Liu LH, Kozel P, Periasamy M, Lorenz JN et al. Physiological function of plasma membrane and intracellular Ca2+ pumps revealed by analysis of null mutants. Ann NY Acad Sci 2003; 986: 453–460. [DOI] [PubMed] [Google Scholar]
  42. Mandal D, Woolf TB, Rao R. Manganese selectivity of pmr1, the yeast secretory pathway ion pump, is defined by residue Gln783 in transmembrane segment 6. Residue Asp778 is essential for cation transport. J Biol Chem 2000; 275: 23933–23938. [DOI] [PubMed] [Google Scholar]
  43. Mandal D, Rulli SJ, Rao R. Packing interactions between transmembrane helices alter ion selectivity of the yeast golgi Ca2+/Mn2+-ATPase PMR1. J Biol Chem 2003; 278: 35292–35298. [DOI] [PubMed] [Google Scholar]
  44. Kinzle C, Basnet N, Crevenna AH, Beck G, Habermann B, Mizuno N et al. Cofilin recruits F-actin to SPCA1 and promotes Ca2+-mediated secretory cargo sorting. J Cell Biol 2014; 206: 635–654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Chun SI, Whang KC, Su WP. Squamous cell carcinoma arising in Hailey–Hailey disease. J Cutan Pathol 1988; 5: 234–237. [DOI] [PubMed] [Google Scholar]
  46. Cockayne SE, Rassl DM, Thomas SE. Squamous cell carcinoma arising in Hailey–Hailey disease of the vulva. Br J Dermatol 2000; 142: 540–542. [DOI] [PubMed] [Google Scholar]
  47. Holst VA, Fair KP, Wilson BG, Patterson JW. Squamous cell carcinoma arising in Hailey–Hailey disease. J Am Acad Dermatol 2000; 43: 368–371. [DOI] [PubMed] [Google Scholar]
  48. Okunade GW, Miller ML, Azhar M, Andringa A, Sanford LP, Doetschman T et al. Loss of the Atp2c1 secretory pathway Ca(2+)-ATPase (SPCA1) in mice causes golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes. J Biol Chem 2007; 282: 26517–26527. [DOI] [PubMed] [Google Scholar]
  49. Shull GE, Miller ML, Prasad V. Secretory pathway stress responses as possible mechanisms of disease involving golgi Ca2+ pump dysfunction. Biofactors 2011; 37: 150–158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Micaroni M, Malquori L. Overlapping ATP2C1 and ASTE1 genes in human genome: implications for SPCA1 isoforms expression? Int J Mol Sci 2013; 14: 674–683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Cosson P, Letourneur F. Coatomer interaction with di-lysine endoplasmic reticulum retention motifs. Science 1994; 263: 1629–1631. [DOI] [PubMed] [Google Scholar]
  52. Letourneur F, Gaynor EC, Hennecke S, Demolliere C, Duden R, Emr SD et al. Coatomer is essential for retrieval of dilysine-tagged proteins to the endoplasmic-reticulum. Cell 1994; 79: 1199–1207. [DOI] [PubMed] [Google Scholar]
  53. Contreras I, Yang Y, Robinson DG, Aniento F. Sorting signals in the cytosolic tail of plant p24 proteins involved in the interaction with the COPII coat. Plant Cell Physiol 2004; 45: 1779–1786. [DOI] [PubMed] [Google Scholar]
  54. Tu L, Tai WC, Chen L, Banfield DK. Signal-mediated dynamic retention of glycosyltransferases in the golgi. Science 2008; 321: 404–407. [DOI] [PubMed] [Google Scholar]
  55. Gao G, Cai Y, Wang Y, Kang BH, Aniento F, Robinson DG et al. Retention mechanisms for ER and golgi membrane proteins. Trend Plant Sci 2014; 19: 508–515. [DOI] [PubMed] [Google Scholar]
  56. Woo CH, Gao C, Yu P, Tu L, Meng Z, Banfield DK et al. Conserved function of the lysine-based KXD/E motif in golgi retention for endomembrane proteins among different organisms. Mol Biol Cell 2015; 26: 4280–4293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Micaroni M. The role of calcium in intracellular trafficking. Curr Mol Med 2010; 10: 763–773. [DOI] [PubMed] [Google Scholar]
  58. Hung AY, Sheng M. PDZ domains: structural modules for protein complex assembly. J Biol Chem 2002; 277: 5699–5702. [DOI] [PubMed] [Google Scholar]
  59. Jemth P, Gianni S. PDZ domains: folding and binding. Biochemestry 2007; 46: 8701–8708. [DOI] [PubMed] [Google Scholar]
  60. D'Angelo G, Prencipe L, Iodice L, Beznoussenko G, Savarese M, Marra P et al. GRASP65 and GRASP55 sequentially promote the transport of C-terminal valine-bearing cargos to and through the golgi complex. J Biol Chem 2009; 284: 34849–34860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Barr FA, Puype M, Vandekerckhove J, Warren G. GRASP65, a protein involved in the stacking of golgi cisternae. Cell 1997; 91: 253–262. [DOI] [PubMed] [Google Scholar]
  62. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 1997; 272: 23389–23397. [DOI] [PubMed] [Google Scholar]
  63. Antebi A, Fink GR. The yeast Ca2+-ATPase homologue, PMR1, is required for normal golgi function and localizes in a novel golgi-like distribution. Mol Biol Cell 1992; 3: 633–654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Varki A. Factors controlling the glycosylation potential of the golgi apparatus. Trends Cell Biol 1998; 8: 34–40. [DOI] [PubMed] [Google Scholar]
  65. Callewaert G, Parys JB, De Smedt H, Raeymaekers L, Wuytack F, Vanoevelen J et al. Similar Ca2+-signaling properties in keratinocytes and in COS-1 cells overexpressing the secretory-pathway Ca2+-ATPase SPCA1. Cell Calcium 2003; 34: 157–162. [DOI] [PubMed] [Google Scholar]
  66. Harper C, Wootton L, Michelangeli F, Lefièvre L, Barratt C, Publicover S. Secretory pathway Ca2+-ATPase (SPCA1) Ca2+-pumps, not SERCAs, regulate complex [Ca2+]i signals in human spermatozoa. J Cell Sci 2005; 118: 1673–1685. [DOI] [PubMed] [Google Scholar]
  67. Foggia L, Aronchik I, Aberg K, Brown B, Hovnanian A, Mauro TM. Activity of the hSPCA1 golgi Ca2+-pump is essential for Ca2+-mediated Ca2+ response and cell viability in Darier disease. J Cell Sci 2006; 119: 671–679. [DOI] [PubMed] [Google Scholar]
  68. Baron S, Struyf S, Wuytack F, Van Damme J, Missiaen L, Raeymaekers L et al. Contribution of intracellular Ca2+ stores to Ca2+ signaling during chemokinesis of human neutrophil granulocytes. Biochim Biophys Acta 2009; 1793: 1041–1049. [DOI] [PubMed] [Google Scholar]
  69. Lai P, Michelangeli F. Changes in expression and activity of the secretory pathway Ca2+ ATPase 1 (SPCA1) in A7r5 vascular smooth muscle cells cultured at different glucose concentrations. Biosci Rep 2009; 29: 397–404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Micaroni M, Perinetti G, Di Giandomenico D, Bianchi K, Spaar A, Mironov AA. Synchronous intra-golgi transport induces release of Ca2+-from the golgi apparatus. Exp Cell Res 2010; 316: 2071–2086. [DOI] [PubMed] [Google Scholar]
  71. Ramos-Castañeda J, Park YN, Liu M, Hauser K, Rudolph H, Shull GE et al. Deficiency of ATP2C1, a golgi ion pump, induces secretory pathway defects in endoplasmic reticulum (ER)-associated degradation and sensitivity to ER stress. J Biol Chem 2005; 280: 9467–9473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sepúlveda MR, Vanoevelen J, Raeymaekers L, Mata AM, Wuytack F. Silencing the SPCA1 (secretory pathway Ca2+-ATPase isoform 1) impairs Ca2+ homeostasis in the golgi and disturbs neural polarity. J Neurosci 2009; 29: 12174–12182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Lissandron V, Podini P, Pizzo P, Pozzan T. Unique characteristics of Ca2+ homeostasis of the trans-golgi compartment. Proc Natl Acad Sci USA 2010; 107: 9198–9203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Van Baelen K, Dode L, Vanoevelen J, Callewaert G, De Smedt H, Missiaen L et al. The Ca2+/Mn2+ pumps in the golgi apparatus. Biochim Biophys Acta 2004; 1742: 103–112. [DOI] [PubMed] [Google Scholar]
  75. Cottrell GS, Hooper NM, Turner AJ. Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single manganese(II)-dependent enzyme. Biochemistry 2000; 39: 15121–15128. [DOI] [PubMed] [Google Scholar]
  76. Davidson HW, Rhodes CJ, Hutton JC. Intraorganellar calcium and pH control proinsulin cleavage in the pancreatic beta cell via two distinct site-specific endopeptidases. Nature 1988; 333: 93–96. [DOI] [PubMed] [Google Scholar]
  77. Mishiro E, Liu MY, Sakakibara Y, Suizo M, Liu MC. Zebrafish tyrosylprotein sulfotransferase: molecular cloning, expression, and functional characterization. Biochem Cell Biol 2004; 82: 295–303. [DOI] [PubMed] [Google Scholar]
  78. Tkacz JS, Herscovics A, Warren CD, Jeanloz RW. Mannosyltransferase activity in calf pancreas microsomes. Formation from guanosine diphosphate-D-(14C)mannose of a 14C-labeled mannolipid with properties of dolichyl mannopyranosyl phosphate. J Biol Chem 1974; 249: 6372–6381. [PubMed] [Google Scholar]
  79. Curwin AJ, von Blume J, Malhotra V. Cofilin-mediated sorting and export of specific cargo from the golgi apparatus in yeast. Mol Biol Cell 2012; 23: 2327–2338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. von Blume J, Alleaume AM, Kienzle C, Carreras-Sureda A, Valverde M, Malhotra V. Cab45 is required for Ca(2+)-dependent secretory cargo sorting at the trans-golgi network. J Cell Biol 2012; 199: 1057–1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. von Blume J, Alleaume AM, Cantero-Recasens G, Curwin A, Carreras-Sureda A, Zimmermann T et al. ADF/cofilin regulates secretory cargo sorting at the TGN via the Ca2+ ATPase SPCA1. Dev Cell 2011; 20: 652–662. [DOI] [PubMed] [Google Scholar]
  82. Grice DM, Vetter I, Faddy HM, Kenny PA, Roberts-Thomson SJ, Monteith GR. Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1) is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. J Biol Chem 2010; 285: 37458–37466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Delva E, Tucker DK, Kowalczyk AP. The desmosome. Cold Spring Harb Perspect Biol 2009; 1: a002543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Bornslaeger EA, Corcoran CM, Stappenbeck TS, Green KJ. Breaking the connection: displacement of the desmosomal plaque protein desmoplakin from cell–cell interfaces disrupts anchorage of intermediate filament bundles and alters intercellular junction assembly. J Cell Biol 1996; 134: 985–1001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Raiko L, Siljamäki E, Mahoney MG, Putaala H, Suominen E, Peltonen J et al. Hailey–Hailey disease and tight junctions: Claudins 1 and 4 are regulated by ATP2C1 gene encoding Ca(2+) /Mn(2+) ATPase SPCA1 in cultured keratinocytes. Exp Dermatol 2012; 21: 586–591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Brini M, Carafoli E. Calcium pumps in health and disease. Physiol Rev 2009; 89: 1341–1378. [DOI] [PubMed] [Google Scholar]
  87. Luo S, Ni H, Li Y, Hou S, Li X, Liu Q. Novel clinical and molecular findings in Chinese families with Hailey–Hailey disease. Clin Exp Dermatol 2011; 36: 814–816. [DOI] [PubMed] [Google Scholar]
  88. Micaroni M. Correct reading frame helps to properly identify ATP2C1 gene mutations vs polymorphisms. Clin Exp Dermatol 2016. (doi:10.1111/ced.12836). [DOI] [PubMed]
  89. Li H, Sun X, Bu D, Zhu X. Study on gene mutation in 11 chinese families with Hailey–Hailey disease. Beijing Da Xue Xue Bao 2003; 35: 390–393. [PubMed] [Google Scholar]
  90. Micaroni M. Misinterpretation of ATP2C1 mutations. Indian J Dermatol Venereol Leprol 2016; 82: 306–307. [DOI] [PubMed] [Google Scholar]
  91. Chao SC, Lee JYY, Wu MC, Hsu MML. A novel splice mutation in the ATP2C1 gene in a woman with concomitant psoriasis vulgaris and disseminated Hailey–Hailey disease. Int J Dermatol 2012; 51: 947–951. [DOI] [PubMed] [Google Scholar]
  92. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol 1999; 292: 195–202. [DOI] [PubMed] [Google Scholar]
  93. Nugent T, Jones DT. Transmembrane protein topology predictions using support vector machines. BMC Bioinformatics 2009; 10: 159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Disfani FM, Hsu WL, Mizianty MJ, Oldfield CJ, Xue B, Dunker AK et al. MoRFpred, a computational tool for sequence-based prediction and characterization of short disorder-to-order transitioning binding regions in proteins. Bioinformatics 2012; 28: i75–i83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Zhang ZZ, Liang YH, Quan C, Gao M, Xiao FL, Yang S et al. Three novel ATP2C1 mutations in Chinese patients with Hailey–Hailey disease. Br J Dermatol 2008; 158: 831–833. [DOI] [PubMed] [Google Scholar]
  96. Li X, Zhang D, Xiao S, Peng Z. Four novel mutations of the ATP2C1 gene in Chinese patients are associated with familial binign chronic pemphigus. Clin Exp Dermatol 2012; 37: 797–799. [DOI] [PubMed] [Google Scholar]
  97. Tian H, Chen M, You J, Fu X, Liu H, Shi Z et al. Six novel mutations of ATP2C1 identified in eight Chinese patients with Hailey–Hailey disease. Indian J Dermatol Venereol Leprol 2013; 79: 245–247. [DOI] [PubMed] [Google Scholar]
  98. Shi BJ, Xiao S, Zhang Z, Lu J, Xue M, Jiang Y et al. The ATP2C1 gene in Hailey–Hailey disease patients: one novel deletion and one novel splicing mutation. J Eur Acad Dermatol Venereol 2015; 29: 2495–2497. [DOI] [PubMed] [Google Scholar]
  99. Zhang GL, Sun YT, Shi HJ, Gu Y, Shao MH, Du XF. Mutation analysis of ATP2C1 gene in a Chinese family with Hailey–Hailey disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010; 27: 414–416. [DOI] [PubMed] [Google Scholar]
  100. Shibata A, Sugiura K, Kimura U, Takamori K, Akiyama M. A novel ATP2C1 early truncation mutation suggests haploinsufficiency as a pathogenic mechanism in a patient with Hailey–Hailey disease. Acta Derm Venereol 2013; 93: 719–720. [DOI] [PubMed] [Google Scholar]
  101. Zhang ZZ, Li W, Zhou FS, Gao M, Xiao FL, Fang QY et al. Identification of a novel mutation in the ATP2C1 gene in a Chinese pedigree with Hailey–Hailey disease. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007; 29: 163–166. [PubMed] [Google Scholar]
  102. Zhang ZZ, Quan C, Mu YZ, Yang H et al. Study on the mutations of ATP2C1 gene in six cases with familial benign chronic pemphigus. Chin J Dermatol 2014; 28: 441–443. [Google Scholar]
  103. Pernet C, Bessis D, Savignac M, Tron E, Guillot B, Hovnanian A. Genitoperineal popular acantholytic dysckeratosis is allelic to Hailey–Hailey disease. Br J Dermatol 2012; 167: 210–212. [DOI] [PubMed] [Google Scholar]
  104. Zhang F, Yan X, Jiang D, Tian H, Wang C, Yu L. Eight novel mutations of ATP2C1 identified in 17 Chinese families with Hailey–Hailey disease. Dermatology 2007; 215: 277–283. [DOI] [PubMed] [Google Scholar]
  105. Tian H, Yan X, Liu H, Yu Y, Zhang F. Six novel mutations identified in Chinese patients with Hailey–Hailey disease. J Dermatol Sci 2010; 58: 80–82. [DOI] [PubMed] [Google Scholar]
  106. Chang HQ, Xiao FL, Zhou FS, Fang QY et al. Mutation detection of the ATP2C1 gene in a Chinese family with Hailey–Hailey disease. Acta Univer Med Anhui 2008; 43: 212–214. [Google Scholar]
  107. Meng L, Gu Y, Du XF, Shao MH, Zhang LL, Zhang GL et al. Two novel ATP2C1 mutations in patients with Hailey–Hailey disease and a literature review of sequence variants reported in Chinese population. Genet Mol Res 2015; 14: 19349–19359. [DOI] [PubMed] [Google Scholar]
  108. Xu Z, Zhang L, Xiao Y, Li L, Lin Z, Yang Y et al. A case of Hailey–Hailey disease in an infant with a new ATP2C1 gene mutation. Pediatric Dermatol 2011; 28: 165–168. [DOI] [PubMed] [Google Scholar]
  109. Iijima S, Hamada T, Kanzaki M, Ohata C, Hashimoto T. Sibling cases of Hailey–Hailey disease showing atypical clinical features and unique disease course. JAMA Dermatol 2014; 150: 97–99. [DOI] [PubMed] [Google Scholar]
  110. Xing XS, Wang Z, Liu S, Wu YH, Zhang SF, Wang SS et al. Three novel mutations of the ATP2C1 gene in Chinese families with Hailey–Hailey disease. J Eur Acad Dermatol Venereol 2016; 30: 1057–1059. [DOI] [PubMed] [Google Scholar]
  111. Ma YM, Zhang XJ, Liang YH, Ma L, Sun LD, Zhou FS et al. Genetic diagnosis in a Chinese Hailey–Hailey disease pedigree with novel ATP2C1 mutation. Arch Dermatol Res 2008; 300: 203–207. [DOI] [PubMed] [Google Scholar]
  112. Cheng YU, Cheng YM, Zhao G, Jia MC. A novel missense mutation of the ATP2C1 gene in a Chinese patient with Hailey–Hailey disease. Biochem Biophys Res Commun 2011; 406: 420–422. [DOI] [PubMed] [Google Scholar]
  113. Ding TG, Fang H, Lao LM, Jiang XJ, Chen HC. Genetic diagnosis of Hailey–Hailey disease in two Chinese families: novel mutations in the ATP2C1 gene. Clin Exp Dermatol 2009; 34: e968–e971. [DOI] [PubMed] [Google Scholar]
  114. Ohtsuka T, Okita H, Hama N, Yamazaki S. Novel mutation of ATP2C1 gene in a Japanese patient with Hailey–Hailey disease. Dermatology 2006; 212: 194–197. [DOI] [PubMed] [Google Scholar]
  115. Matsuda M, Hamada T, Numata S, Teye K, Ishii N, Ohata C et al. A three-dimensional in vitro culture model of Hailey–Hailey disease. Exp Dermatol 2015; 24: 788–789. [DOI] [PubMed] [Google Scholar]
  116. Wang CC, Chao SC, Tsai TH. Hailey–Hailey disease: a novel mutation of the ATP2C1 gene in a Taiwanese family with divergent clinical presentation. J Eur Acad Dermatol Venereol 2008; 22: 1145–1146. [DOI] [PubMed] [Google Scholar]
  117. Xu QQ, Cheng CZ, Huo J, Liu Y et al. Detection of ATP2C1 gene mutations in two Chinese families with Hailey–Hailey disease. Chin J Dermatol 2012; 26: 475–476. [Google Scholar]
  118. Li XL, Peng ZH, Xiao SX, Wang ZH, Liu Y, Pan M et al. A novel deletion mutation of the ATP2C1 gene in Chinese patients with Hailey–Hailey disease. J Eur Acad Dermatol Venereol 2008; 22: 235–262. [DOI] [PubMed] [Google Scholar]
  119. Yokota K, Sawamura D. Hailey–Hailey disease with affective disorder: report of a case with novel ATP2C1 gene mutation. J Dermatol Sci 2006; 43: 150–151. [DOI] [PubMed] [Google Scholar]
  120. Szigeti R, Chao SC, Szász O, Tészás A, Kosztolányi G, Kellermayer R. Premenstrual exacerbation in calcium ATPase disorders of the skin. J Eur Acad Dermatol Venereol 2007; 21: 412–413. [DOI] [PubMed] [Google Scholar]
  121. Mizuno K, Hamada T, Hashimoto T, Okamoto H. Successful treatment with narrow-band UVB therapy for a case of generalized Hailey–Hailey disease with a novel splice-site mutation in ATP2C1 gene. Dermatol Ther 2014; 27: 233–235. [DOI] [PubMed] [Google Scholar]
  122. Zhu YG, Yang S, Gao M, Chen JJ, Li W, Wang PG et al. Two novel mutations of the ATP2C1 gene in Chinese families with Hailey–Hailey disease. J Dermatol Sci 2006; 42: 125–127. [DOI] [PubMed] [Google Scholar]
  123. Yin CH, Wang BX, Ma DL. Gene mutations in a Chinese family with Hailey–Hailey disease. Chin J Dermatol 2003; 36: 507–509. [Google Scholar]
  124. Li X, Xiao S, Peng Z, Liu Y, Wang J, Zhou X. Two novel mutations of the ATP2C1 gene in Chinese patients with Hailey–Hailey disease. Arch Dermatol Res 2007; 299: 209–211. [DOI] [PubMed] [Google Scholar]
  125. Poblete-Gutiérrez P, Wiederholt T, König A, Jugert FK, Marquardt Y, Rübben A et al. Allelic loss underlies type 2 segmental Hailey–Hailey disease, providing molecular confirmation of a novel genetic concept. J Clin Invest 2004; 114: 1467–1474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Liu JZ, Yang T, Li X, Liu M, Wang QK, Liu JY. A novel mutation in the ATP2C1 gene is associated with Hailey–Hailey disease in a Chinese family. Int J Dermatol 2009; 48: 47–51. [DOI] [PubMed] [Google Scholar]
  127. Lipoff JB, Mudgil AV, Young S, Chu P, Cohen SR. Acantholytic dermatosis of the crural folds with ATP2C1 mutation is a possible variant of Hailey–Hailey disease. J Cutan Med Surg 2009; 13: 151–154. [DOI] [PubMed] [Google Scholar]
  128. Chen S, Huang C, Li J. Detection of ATP2C1 gene mutation in familial benign chronic pemphigus. J Huazhong Univ Sci Technolog Med Sci 2005; 25: 585–586. [DOI] [PubMed] [Google Scholar]
  129. Van Beek N, Patsatsi A, Gupta Y, Moller S, Freitag M, Lemcke S et al. A family with atypical Hailey–Hailey disease—is there more to the underlying genetics than ATP2C1? PLoS One 2015; 10: e121253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Chen SY, Huang CZ, Li JW. Mutation detection of ATP2C1 gene in a Chinese family with Hailey–Hailey disease. Chin J Dermatol 2004; 37: 550. [Google Scholar]
  131. Makino T, Shimizu K, Mizawa M, Nakano H, Sawamura D, Shimizu T. A novel deletion mutation of the ATP2C1 gene in a family with Hailey–Hailey disease. Eur J Dermatol 2015. (doi:10.1684/ejd.2015.2592). [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1

Articles from Cell Death & Disease are provided here courtesy of Nature Publishing Group

RESOURCES